EGFR and neoplasm: A hazard ratio (HR) of 1.63 in patients with non-small-cell lung cancer (NSCLC) with bone metastases compared to those without metastasis indicated that patients in the former group had a worse overall survival (OS), with KRAS and EGFR mutations in circulating tumor DNA (ctDNA) being linked to this poorer outcome [63].